Quantification of CD31 stained A2780cisR tumor sections revealed a decrease in MVD for erlotinib and RAPTA-C mono-therapies (i.e. 19% for erlotinib at 20 μg/kg/day and 28% for RAPTA-C at 216 μg/kg/day, Fig. 6C). This evidence concerns the gene PECAM1 and neoplasm.